AMGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 276.9 USD | -0.16% |
|
+3.17% | -3.51% |
| 12:56pm | Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn | MT |
| 11:04am | European Midday Briefing : Stocks Steady as Powell Suggests Rate Hike Unlikely | DJ |
Financials (USD)
| Sales 2024 * | 32.95B | Sales 2025 * | 34.14B | Capitalization | 149B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.11B | Net income 2025 * | 7.56B | EV / Sales 2024 * | 5.93 x |
| Net Debt 2024 * | 46.47B | Net Debt 2025 * | 40.28B | EV / Sales 2025 * | 5.54 x |
| P/E ratio 2024 * |
24.2
x | P/E ratio 2025 * |
18.7
x | Employees | 26,700 |
| Yield 2024 * |
3.34% | Yield 2025 * |
3.62% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
| 1 day | +1.26% | ||
| 1 week | +1.61% | ||
| Current month | +1.26% | ||
| 1 month | -1.99% | ||
| 3 months | -14.53% | ||
| 6 months | +6.35% | ||
| Current year | -3.69% |
1 week
265.72
279.84
1 month
260.68279.84
Current year
260.68329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.30329.72
10 years
109.41329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | Dec. 17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 120 M€ | +11.38% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 277.9 | +0.19% | 587 561 |
| 24-05-01 | 277.4 | +1.25% | 2,323,935 |
| 24-04-30 | 273.9 | -0.88% | 2,477,347 |
| 24-04-29 | 276.4 | +2.37% | 2,678,969 |
| 24-04-26 | 270 | +0.22% | 2,436,959 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
277.4
USD
Average target price
303.3
USD
Spread / Average Target
+9.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.69% | 149B | |
| +33.25% | 699B | |
| +26.47% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +15.08% | 236B | |
| +4.76% | 198B | |
| -10.22% | 194B | |
| -5.59% | 154B |
- Stock Market
- Equities
- AMGN Stock
